At-home Leqembi initiation arrived in 2026, but MRI monitoring for ARIA did not go away for people with mild cognitive impairment. Home injections replace early infusion visits, yet clinic brain scans after about 1, 2, 3 and 6 months still check for brain changes.
ARIA means amyloid-related imaging abnormalities. ARIA-E is swelling or edema, and ARIA-H involves bleeding-related signals such as microhemorrhages and surface iron deposits. Leqembi is lecanemab, a treatment for early Alzheimer's disease that removes amyloid from the brain.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What home initiation changed
- Who can receive it
- Why MRI monitoring stayed mandatory
- What home treatment still requires
What home initiation changed
Before July 2026, at-home Leqembi was maintenance only. The Alzheimer's Association notes the FDA had approved 360 mg weekly under the skin only after 18 months of vein infusions. That changed on July 13, 2026. According to NeurologyLive, the agency approved Leqembi Iqlik 500 mg once weekly as two 250-mg autoinjector injections in the FDA approval report.
Treatment can now start at home without first completing long-term infusions. For families, the difference is travel and time. Home dosing can remove dozens of infusion-center visits during the starting period. Clinic visits remain necessary for other parts of care.
Who can receive it
The eligible group did not change. Eisai and Biogen state the indication remains adults with mild cognitive impairment or mild dementia due to Alzheimer's disease. A doctor must also confirm amyloid in the brain.
Mild cognitive impairment means early, measurable memory or thinking changes that do not yet prevent daily independence. People without confirmed amyloid pathology are not candidates. Care partners should confirm diagnosis, amyloid test results, and overall health fit before planning home starts. Early Alzheimer's care still begins with careful patient selection, not with the injection device alone.
Why MRI monitoring stayed mandatory
Current labeling requires a recent baseline brain MRI plus follow-ups after about 1, 2, 3 and 6 months to detect ARIA. According to Medscape, these scans remain required even when injections happen at home in the home-treatment overview. The scans look for silent swelling or bleeding before symptoms appear. The FDA also added earlier surveillance on Aug. 28, 2025.
According to the FDA Drug Safety Communication, labeling must include MRI between the second and third infusion to find ARIA-edema sooner in the safety update. Early checks matter because ARIA often starts without symptoms. Lecanemab retains a boxed warning for ARIA-E and ARIA-H. These events can become serious or fatal, with highest vigilance during the first 14 weeks. A missed or delayed MRI can leave a treatable signal unseen.
What home treatment still requires
Home use shifts where the drug is given, not how safety is managed. Patients still need in-clinic MRIs, ApoE-e4 counseling, caregiver training, and clinician oversight. U.S.
initiation supply moved through specialty pharmacy from late August 2026. Families can plan for: One limitation matters for expectations. NeurologyLive reports the under-the-skin approval relied on comparable drug exposure and amyloid removal, including modeling and 2026 meeting data, not a new large outcomes trial like the IV Clarity AD result of 27 percent less decline on CDR-SB. Patients gain home convenience without new proof of greater memory benefit.
- scheduled MRI travel on the baseline and follow-up timetable
- ApoE-e4 gene testing discussion and risk counseling
- hands-on injection training and storage review
- a clear contact plan for headache, confusion, dizziness, vision change, or other new symptoms
You Might Also Like
- At-Home Leqembi vs IV Infusions After the 2026 FDA Decision: What Changed and What Did Not for People With Mild Cognitive Impairment
- PrecivityAD2 Testing for Symptomatic Adults 40 and Older in 2026: What Is Established and What Remains Uncertain for People With Mild Cognitive Impairment
- Subjective Cognitive Decline Data for Public Health Action in 2026: How Adults in Midlife Can Read the Headline Carefully





